4//SEC Filing
Shawver Laura 4
Accession 0001415889-25-001053
CIK 0001671858other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 6:24 PM ET
Size
8.9 KB
Accession
0001415889-25-001053
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Exercise/Conversion
Common Stock
2025-01-06$3.15/sh+50,000$157,500→ 260,346 total - Sale
Common Stock
2025-01-06$11.10/sh−50,000$555,065→ 210,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-06−50,000→ 9,064 totalExercise: $3.15Exp: 2032-05-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001551891
Filing Metadata
- Form type
- 4
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 6:24 PM ET
- Size
- 8.9 KB